256:
Crawford, Thomas; Place, Amy; Barrett, Doreen; Cote, Shaun; Nomikos, George; Song, Guochen; Bilic, Sanela; Kalra, Ashish; Sadanowicz, Mara; O'Neil, Janet; Iarrobino, Ryan; Kertesz, Nathalie; Chyung, Yung (2021). "Relationship of pharmacokinetics and pharmacodynamics to apitegromab efficacy in
224:
Crawford, Thomas; Darras, Basil; Day, John; Song, Guochen; Nomikos, George; Place, Amy; Barrett, Doreen; Bilic, Sanela; O‘Neil, Janet; Kertesz, Nathalie; Cote, Shaun; Patel, Jagdish; Chyung, Yung (3 May 2022).
166:
Barrett, Doreen; Bilic, Sanela; Chyung, Yung; Cote, Shaun M.; Iarrobino, Ryan; Kacena, Katherine; Kalra, Ashish; Long, Kimberly; Nomikos, George; Place, Amy; Still, James Gordon; Vrishabhendra, Leela (2021).
169:"A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy"
31:
303:
298:
308:
227:"Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis of Multiple Efficacy Endpoints in the TOPAZ Trial (P15-5.005)"
133:, which limits the size of skeletal muscle tissue, as well as inactive myostatin. It does not bind to active myostatin,
89:
146:
122:
257:
patients with later-onset spinal muscular atrophy (Types 2 and 3 SMA): Results from the TOPAZ study".
118:
69:
24:
126:
274:
238:
206:
188:
138:
78:
266:
196:
180:
98:
226:
201:
168:
292:
278:
184:
270:
242:
192:
134:
130:
17:
210:
142:
41:
88:
68:
63:
55:
50:
40:
30:
23:
77:
8:
16:
200:
97:
125:. It works by binding to and inhibiting
158:
15:
7:
259:Journal of the Neurological Sciences
14:
1:
325:
185:10.1007/s12325-021-01757-z
271:10.1016/j.jns.2021.118388
147:activin type 2 receptors
145:that all operate on the
304:Spinal muscular atrophy
123:spinal muscular atrophy
299:Monoclonal antibodies
309:Myostatin inhibitors
173:Advances in Therapy
121:developed to treat
119:monoclonal antibody
117:) is a fully human
25:Monoclonal antibody
20:
237:(18 Supplement).
129:, a precursor to
108:
107:
316:
283:
282:
253:
247:
246:
221:
215:
214:
204:
179:(6): 3203–3222.
163:
101:
81:
21:
19:
324:
323:
319:
318:
317:
315:
314:
313:
289:
288:
287:
286:
255:
254:
250:
223:
222:
218:
165:
164:
160:
155:
104:
84:
12:
11:
5:
322:
320:
312:
311:
306:
301:
291:
290:
285:
284:
248:
216:
157:
156:
154:
151:
106:
105:
103:
102:
94:
92:
86:
85:
83:
82:
74:
72:
66:
65:
61:
60:
57:
53:
52:
48:
47:
44:
38:
37:
34:
28:
27:
13:
10:
9:
6:
4:
3:
2:
321:
310:
307:
305:
302:
300:
297:
296:
294:
280:
276:
272:
268:
264:
260:
252:
249:
244:
240:
236:
232:
228:
220:
217:
212:
208:
203:
198:
194:
190:
186:
182:
178:
174:
170:
162:
159:
152:
150:
148:
144:
140:
136:
132:
128:
124:
120:
116:
112:
100:
96:
95:
93:
91:
87:
80:
76:
75:
73:
71:
67:
62:
58:
54:
51:Clinical data
49:
45:
43:
39:
35:
33:
29:
26:
22:
262:
258:
251:
234:
230:
219:
176:
172:
161:
127:promyostatin
114:
110:
109:
79:2278276-46-1
46:Promyostatin
111:Apitegromab
64:Identifiers
56:Other names
18:Apitegromab
293:Categories
265:: 118388.
153:References
99:UZ54216N0Y
70:CAS Number
279:238481481
243:0028-3878
231:Neurology
193:0741-238X
137:, active
135:activin A
131:myostatin
211:33963971
202:8189951
139:BMP9/10
115:SRK-015
59:SRK-015
277:
241:
209:
199:
191:
42:Target
275:S2CID
143:TGFβ1
239:ISSN
207:PMID
189:ISSN
90:UNII
32:Type
267:doi
263:429
197:PMC
181:doi
141:or
295::
273:.
261:.
235:98
233:.
229:.
205:.
195:.
187:.
177:38
175:.
171:.
149:.
281:.
269::
245:.
213:.
183::
113:(
36:?
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.